Interferon alfa as primary treatment of chronic myeloid leukemia: Long-term follow-up of 71 patients observed in a single center

Leukemia

Volumn 14, Issue 3, 2000, Pages 389-392

  Kloke, O ^a   Opalka, B ^a   Niederle, N ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CML; Cytogenetic remission; Interferon alfa

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON;

ADULT; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034052092     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401661     Document Type: Article

References (12)

1. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069-3081.
2. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
3. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 1616-1620.
4. Hasford J, Pfirrmann M, Hehlmann R, Allen NC, Baccarani M, Kluin-Nelemanns JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998: 90: 850-858.
5. Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, Opalka B, Seeber S, Becher R. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993; 83: 399-403.
6. Kloke O, Wandl U, Opalka B, Moritz T, Nagel-Hiemke M, Franz T, Hirche H, Seeber S, Niederle N. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. Eur J Haematol 1992; 48: 93-98.
7. Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B. Long-term treatment chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymphoma 1993; 9: 111-119.
8. Talpaz M, Kantarjian HM, McCredie KB, Trujillo K, Keating MJ, Gutterman JU. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 72: 1280-1288.
9. Kaplan EM, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
11. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541-1548.
12. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falga C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, von Wussow P, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, and the German CML study group. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.